US Patent No: 7,902,213

Number of patents in Portfolio can not be more than 2000

Pharmaceutical cream with reduced imiquimod impurities at four months using refined oleic acid

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Pharmaceutical formulations and methods including an immune response modifier (IRM) compound and an oleic acid component are provided where stability is improved by using oleic acid have low polar impurities such as peroxides.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BARCLAYS BANK PLC, AS SUCCESSOR AGENTLONDON783
MEDICIS PHARMACEUTICAL CORPORATIONSCOTTSDALE, AZ114

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Nelson, Robert J Cottage Grove, US 92 2255
Statham, Alexis S Woodbury, US 36 483

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
2003/0026,794 Selective enzyme treatment of skin conditions 38 2001
2003/0059,471 Oral delivery formulation 96 2001
 
MINNESOTA MINING AND MANUFACTURING COMPANY (2)
4,411,893 Topical medicament preparations 71 1982
5,346,905 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines 239 1992
 
KYTHERA BIOPHARMACEUTICALS, INC. (1)
2005/0201,959 Methods and compositions for altering skin coloration 31 2004
 
ALZA CORPORATION (2)
4,746,515 Skin permeation enhancer compositions using glycerol monolaurate 107 1987
6,210,712 Dosage form having first and second coats 49 1998
 
NUVO RESEARCH INC. (1)
2005/0276,842 Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same 63 2005
 
Theratech, Inc. (1)
4,863,970 Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols 200 1988
 
PERICOR SCIENCE, INC. (1)
6,267,957 Attaching agents to tissue with transglutaminase and a transglutaminase substrate 89 1999
 
GRACEWAY PHARMACEUTICALS, LLC (2)
4,689,338 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use 329 1985
5,238,944 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine 243 1992
 
Luitpold Pharmaceuticals, Inc. (1)
5,919,815 Taxane compounds and compositions 110 1996
 
MEPHA AG (1)
2006/0039,931 Stable cream preparations of phenyl-pyridone compounds for topical application 34 2003
 
Takeda Pharmaceutical Company Limited (1)
6,194,425 Imidazonaphthyridines 190 1998
 
Corium International, Inc. (2)
6,803,420 Two-phase, water-absorbent bioadhesive composition 85 2002
2003/0170,308 Hydrogel compositions 90 2002
 
FUJIMORI KOGYO CO., LTD. (1)
4,686,125 Film laminate for sterile flexible containers 103 1984
 
NOVEN PHARMACEUTICALS, INC. (3)
5,300,291 Method and device for the release of drugs to the skin 92 1991
6,562,363 Bioadhesive compositions and methods for topical administration of active agents 168 1998
6,638,528 Compositions and methods to effect the release profile in the transdermal administration of active agents 117 2002
 
COLEY PHARMACEUTICAL GROUP, INC. (10)
5,268,376 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines 241 1991
5,266,575 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines 237 1991
5,352,784 Fused cycloalkylimidazopyridines 235 1993
5,446,153 Intermediates for imidazo[4,5-c]pyridin-4-amines 202 1994
5,482,936 Imidazo[4,5-C]quinoline amines 215 1995
6,376,669 Dye labeled imidazoquinoline compounds 171 2000
6,660,735 Urea substituted imidazoquinoline ethers 140 2002
6,677,347 Sulfonamido ether substituted imidazoquinolines 135 2002
6,677,348 Aryl ether substituted imidazoquinolines 135 2002
2004/0176,367 1-Amino 1H-imidazoquinolines 86 2004
 
ABB TECHNOLOGY AG (1)
2004/0089,855 High oleic acid oil compositions and methods of making and electrical insulation fluids and devices comprising the same 32 2003
 
GALENIX INNOVATIONS (2)
2003/0096,012 Film-forming powder, compositions containing it, methods for their preparation and their uses 63 2002
2003/0124,191 Use of an immediate-release powder in pharmaceutical and nutraceutical compositions 60 2002
 
HENKEL IP & HOLDING GMBH (1)
2002/0128,345 Hot melt adhesives for dermal application 39 2000
 
INTERCONNECTRON GMBH (1)
6,425,776 Circular plug and socket connector for producing electrical line connections 33 2000
 
AGIS INDUSTRIES (1983) LTD. (1)
2006/0034,779 Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same 34 2005
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
2005/0175,630 Immunogenic compositions and methods of use thereof 44 2004
 
ASTRA AKTIEBOLAG (1)
6,103,697 Peptides with immunomodulatory effects 35 1997
 
3M INNOVATIVE PROPERTIES COMPANY (25)
6,039,969 Immune response modifier compounds for treatment of TH2 mediated and related diseases 220 1997
6,110,929 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 194 1999
6,245,776 Formulations and methods for treatment of mucosal associated conditions with an immune response modifier 215 2000
6,200,592 Immine response modifier compounds for treatment of TH2 mediated and related diseases 100 2000
6,331,539 Sulfonamide and sulfamide substituted imidazoquinolines 187 2000
6,451,810 Amide substituted imidazoquinolines 164 2000
6,656,938 Urea substituted imidazoquinoline ethers 141 2001
6,660,747 Amido ether substituted imidazoquinolines 136 2001
6,664,260 Heterocyclic ether substituted imidazoquinolines 130 2001
6,664,264 Thioether substituted imidazoquinolines 141 2001
6,670,372 Aryl ether substituted imidazoquinolines 135 2001
6,683,088 Sulfonamido ether substituted imidazoquinolines 135 2001
6,756,382 Amide substituted imidazoquinolines 108 2001
6,525,064 Sulfonamido substituted imidazopyridines 158 2002
6,545,016 Amide substituted imidazopyridines 154 2002
6,545,017 Urea substituted imidazopyridines 155 2002
6,664,265 Amido ether substituted imidazoquinolines 141 2002
6,667,312 Thioether substituted imidazoquinolines 140 2002
2003/0199,538 Pharmaceutical formulation comprising an immune response modifier 108 2002
6,677,349 Sulfonamide and sulfamide substituted imidazoquinolines 137 2003
6,797,718 Ether substituted imidazopyridines 105 2003
2004/0091,491 Immunostimulatory compositions and methods of stimulating an immune response 95 2003
6,818,650 1H-imidazo dimers 105 2003
2004/0132,766 1H-imidazo dimers 56 2003
2004/0147,543 Aryl substituted imidazoquinolines 90 2003
 
Nippon Oil & Fats Co., Ltd. (1)
4,601,856 Method of purifying oleic acid 35 1985
 
MEDICIS PHARMACEUTICAL CORPORATION (7)
5,389,640 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines 257 1992
5,736,553 Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo?4,5-C!quinolin-4-amine 66 1995
5,939,090 Gel formulations for topical drug delivery 191 1996
6,541,485 Urea substituted imidazoquinolines 149 2000
6,573,273 Urea substituted imidazoquinolines 143 2001
2004/0192,585 Treatment for basal cell carcinoma 84 2004
2007/0167,479 Immune response modifier formulations and methods 51 2005
 
The Procter & Gamble Company (1)
5,008,110 Storage-stable transdermal patch 105 1988
 
WARNER-LAMBERT COMPANY (1)
4,908,389 Penetration enhancement system 54 1986
 
SHISEIDO COMPANY, LTD. (1)
5,472,982 Emulsified external treatment composition containing diclofenac sodium 31 1993
 
Riker Laboratories, Inc. (4)
4,751,087 Transdermal nitroglycerin delivery system 93 1985
4,698,348 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents 269 1985
4,929,624 Olefinic 1H-imidazo(4,5-c)quinolin-4-amines 275 1989
5,756,747 1H-imidazo?4,5-c!quinolin-4-amines 201 1995
 
COGNIS CORPORATION (1)
6,498,261 Process for improving color and color stability of oleic acid 31 1995
 
DERMATRENDS, INC. (1)
2003/0072,814 Topical pharmaceutical composition for the treatment of warts 92 2002
 
LTS LOHMANN THERAPIE-SYSTEME AG (1)
7,056,528 Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin 34 2000
 
Hisamitsu Pharmaceuticals (1)
7,504,114 Preparations for percutaneous absorption 33 2000
 
Purcell Jojoba International, LLC (1)
6,559,182 Method for treatment of enveloped viruses using jojoba oil esters 33 2001
 
VIRUN, INC. (1)
2005/0281,772 Compositions for mucosal delivery of agents 63 2005
 
PERRIGO ISRAEL PHARMACEUTICALS LTD. (1)
2006/0024,243 Foamable compositions containing nitro-imidazoles, processes for preparing same and methods of treatment utilizing same 31 2005
 
RANBAXY LABORATORIES LIMITED (1)
2005/0037,030 Stable topical formulation of clarithromycin 30 2004
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (1)
4,695,465 Soft patch 123 1985
 
A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESES, RUSSIAN ACADEMY OF SCIENCES (1)
2004/0242,770 Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith 59 2004
 
PHARMACIA & UPJOHN COMPANY LLC (1)
2003/0211,163 Combination antiviral therapy 37 2003
 
MITSUI CHEMICALS, INC. (1)
5,532,030 Polyolefin multilayer laminate, vessel and packaging material 68 1995
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
3M INNOVATIVE PROPERTIES COMPANY (27)
8,378,102 ] ring compounds and methods 0 2006
* 2008/0318,998 Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines 44 2006
8,658,666 Substituted imidazoquinolines and imidazonaphthyridines 1 2006
* 2009/0099,161 Substituted Imidazoquinolines and Imidazonaphthyridines 43 2006
8,846,710 Method of preferentially inducing the biosynthesis of interferon 0 2006
8,343,993 Hydroxyalkyl substituted imidazonaphthyridines 0 2006
8,178,677 Hydroxyalkyl substituted imidazoquinolines 1 2006
8,158,794 Hydroxyalkyl substituted imidazoquinoline compounds and methods 1 2006
* 2009/0069,314 Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods 45 2006
* 2009/0029,988 Hydroxyalkyl Substituted Imidazoquinolines 45 2006
8,476,292 Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods 0 2006
8,188,111 -imidazo[4,5-c]quinolin-1-yl)butyI]methanesulfonamides and methods 0 2006
8,088,790 -imidazoquinolines and methods 2 2006
8,329,721 -imidazonaphthyridines and methods 0 2007
8,178,539 ]phenalenes and methods 0 2007
* 2010/0173,906 Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-Tetraazacyclopenta[cd]Phenalenes and Methods 20 2007
8,541,438 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 1 2010
8,263,594 Aryloxy and arylalkyleneoxy substituted imidazoquinolines 0 2011
* 2011/0144,099 ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED IMIDAZOQUINOLINES 1 2011
8,207,162 ] ring compounds 1 2011
8,350,034 Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds 0 2011
9,242,980 Lipidated immune response modifier compound compositions, formulations, and methods 0 2011
8,377,957 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 0 2011
9,145,410 Pyrazolopyridines and analogs thereof 0 2012
8,546,383 Chiral fused [1,2]imidazo[4,5-c] ring compounds 0 2012
9,107,958 Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom 0 2012
9,006,264 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 0 2013
 
MEDICIS PHARMACEUTICAL CORPORATION (6)
* 2010/0160,368 Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy 4 2009
* 2011/0207,766 LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS 1 2010
8,598,196 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy 0 2012
8,642,616 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 0 2012
9,271,973 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy 0 2013
9,078,889 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 0 2013
 
PFIZER INC. (1)
* 2009/0298,821 HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS 23 2007
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 8, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 8, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00